Wedbush cuts Aclaris Therapeutics target price to $8 from $10
ACRS•Wedbush cut its target price for Aclaris Therapeutics to $8 from $10.
Related News
One Stop Systems reports Q3 2026 results
OSS•
Evolus participates in Stifel and Jefferies healthcare conferences
EOLS•
PGIM, LGT Capital Partners co-lead $680 million Tree Line private credit continuation vehicle
PRU•
Amphenol Q3 sales beat estimates on IT datacom growth and acquisitions
APH•
VF management commentary: Gross margin expansion drives fiscal Q2 2027 operating income growth
VFC•